What is the treatment approach for pre-menopausal breast cancer (stages I-IIIA)?

• A. Dependent on hormone receptor status; surgery is primary curative treatment.
• B. Chemotherapy is always first-line.
• C. Radiation therapy alone cures early disease.
• D. Hormone therapy is never used.

Answer: (A)

The key idea is that treatment for early‑stage breast cancer in premenopausal women is guided by tumor biology, especially hormone receptor status, with local control primarily achieved through surgery. For most stage I–IIIA cases, the plan starts with removing the tumor surgically—either by breast‑conserving surgery or mastectomy—with appropriate nodal staging. Radiation therapy is then used as needed to reduce local recurrence after breast‑conserving surgery or in selected mastectomy cases.

Systemic therapy is added based on receptor status. If the tumor is estrogen or progesterone receptor–positive, endocrine therapy is used (in premenopausal women this typically means tamoxifen, with possible ovarian suppression in higher‑risk scenarios). If the tumor is HER2 positive, targeted therapy such as trastuzumab is combined with chemotherapy. In triple‑negative disease, chemotherapy is the main systemic option. This approach would not be described as always starting with chemotherapy, nor as radiation alone curing early disease, nor as never using hormone therapy.